Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

NCT05239182 is registered in ClinicalTrials.gov with Anwaar Saeed as lead sponsor.

NCT NCT05239182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05239182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Lead sponsor
Anwaar Saeed
Phase
Phase 2
Overall status
Terminated
Start date
January 26, 2022
Completion date
February 4, 2024
Enrollment
7 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma